BMC infectious diseases. 2021 Apr 23;21(1):379. doi: 10.1186/s12879-021-06059-x Q23.02025

Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations

喀麦隆重组亚型CRF02_AG毒株中统计富集突变的相互作用分析及其对多替拉韦耐药突变发展的影响翻译改进

Sello Given Mikasi¹, Darren Isaacs², Rumbidzai Chitongo², George Mondide Ikomey³, Graeme Brendon Jacobs¹, Ruben Cloete⁴

作者单位 +展开

作者单位

¹ Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.

² South African Medical Research Council Bioinformatics Unit, South African National Bioinformatics Institute, University of the Western Cape, Robert Sobukwe Rd, Bellville, P.O. Box X17, Cape Town, 7535, South Africa.

³ Centre for the Study and Control of Communicable Diseases, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon.

⁴ South African Medical Research Council Bioinformatics Unit, South African National Bioinformatics Institute, University of the Western Cape, Robert Sobukwe Rd, Bellville, P.O. Box X17, Cape Town, 7535, South Africa. ruben@sanbi.ac.za.

DOI: 10.1186/s12879-021-06059-x PMID: 33892628

摘要 Ai翻译

Background: The Integrase (IN) strand transfer inhibitor (INSTI), Dolutegravir (DTG), has been given the green light to form part of first-line combination antiretroviral therapy (cART) by the World Health Organization (WHO). DTG containing regimens have shown a high genetic barrier against HIV-1 isolates carrying specific resistance mutations when compared with other class of regimens. ... ...点击完成人机验证后继续浏览

相关内容

期刊名：Bmc infectious diseases

缩写：BMC INFECT DIS

ISSN：N/A

e-ISSN：1471-2334

IF/分区：3.0/Q2

文章目录更多期刊信息

全文链接

官方链接

PMC全文

引文链接

复制

已复制！

格式：

Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations

喀麦隆重组亚型CRF02_AG毒株中统计富集突变的相互作用分析及其对多替拉韦耐药突变发展的影响翻译改进

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy

病例报告：二线抗逆转录病毒治疗患者中出现的对多替拉韦的耐药性

Correction to: Major role of dolutegravir in the emergence of the S147G integrase resistance mutation

Correction to: 洛匹那韦在整合酶突变S147G产生中的重要作用纠正文章：

High-level dolutegravir resistance selection on dolutegravir/lamivudine

在使用多替拉韦/拉米夫定时出现高水平的多替拉韦耐药选择

High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy

高水平的多替拉韦抗药性可以迅速从少数变异中产生并通过重组传播：整合酶链转移抑制剂补救治疗的启示

Insights in Dolutegravir-resistance pathways

关于多替拉韦耐药途径的见解

Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir

T97A突变在度鲁特格韦低度敏感基线的2例治疗经验丰富的HIV感染者中快速进展为高水平耐药性

Major role of dolutegravir in the emergence of the S147G integrase resistance mutation

多特拉格韦在S147G整合酶耐药突变出现中的重要作用

Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases

整合酶抑制剂初治患者中拉替拉韦耐药的产生：已发表个案综述

Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations

喀麦隆重组亚型CRF02_AG毒株中统计富集突变的相互作用分析及其对多替拉韦耐药突变发展的影响 翻译改进

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy

病例报告：二线抗逆转录病毒治疗患者中出现的对多替拉韦的耐药性

Correction to: Major role of dolutegravir in the emergence of the S147G integrase resistance mutation

Correction to: 洛匹那韦在整合酶突变S147G产生中的重要作用纠正文章：

High-level dolutegravir resistance selection on dolutegravir/lamivudine

在使用多替拉韦/拉米夫定时出现高水平的多替拉韦耐药选择

High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for integrase strand transfer inhibitor salvage therapy

高水平的多替拉韦抗药性可以迅速从少数变异中产生并通过重组传播：整合酶链转移抑制剂补救治疗的启示

Insights in Dolutegravir-resistance pathways

关于多替拉韦耐药途径的见解

Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir

T97A突变在度鲁特格韦低度敏感基线的2例治疗经验丰富的HIV感染者中快速进展为高水平耐药性

Major role of dolutegravir in the emergence of the S147G integrase resistance mutation

多特拉格韦在S147G整合酶耐药突变出现中的重要作用

Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases

整合酶抑制剂初治患者中拉替拉韦耐药的产生：已发表个案综述

喀麦隆重组亚型CRF02_AG毒株中统计富集突变的相互作用分析及其对多替拉韦耐药突变发展的影响翻译改进